Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8962572 | FRESENIUS KABI USA | Bortezomib formulations |
Nov, 2032
(8 years from now) |
Market Authorisation Date: 06 November, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11752164 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(18 years from now) | |
US11679119 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(18 years from now) |
Market Authorisation Date: 27 July, 2022
Treatment: Treatment of adult patients with mantle cell lymphoma; Treatment of adult patients with multiple myeloma
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6713446 | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jan, 2022
(2 years ago) | |
US6958319 | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jan, 2022
(2 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6713446 (Pediatric) | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jul, 2022
(1 year, 8 months ago) | |
US6958319 (Pediatric) | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jul, 2022
(1 year, 8 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity (PED) | Apr 8, 2022 |
Market Authorisation Date: 13 May, 2003
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS